Long-term follow-up for hepatitis B after imdusiran treatment
Part of Infections clinical trials.
This study is a long-term check-in for people with chronic hepatitis B who were in an earlier trial of the drug imdusiran (AB729) and have stopped their usual hepatitis B medication. It will monitor your health over time to learn more about the effects of stopping treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a previous study of the drug imdusiran (AB729) for chronic hepatitis B.
- During that earlier study, you stopped taking your regular hepatitis B treatment (called a nucleoside analog or NA) and have not restarted it.
- It has been less than 3 years since you stopped that NA treatment in the previous study.
- You must be able to understand and sign an informed consent form and commit to all study visit schedules and rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injected medication called imdusiran (AB-729) to see how it affects the immune system in people with chronic hepatitis B. It is for people who are already stable on oral antivirals and want to try a new approach to possibly control the virus better.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
This trial looks at people with long-term hepatitis B infection and studies how treatment may affect health over time. It may help you understand whether your care improves outcomes for chronic hepatitis B.
Hear when a new Long Term Follow-Up trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.